Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border

David L. Saunders; Suwanna Chaorattanakawee; Panita Gosi; Charlotte Lanteri; Sok Somethy; Worachet Kuntawunginn; Mali Ittiverakul; Soklyda Chann; Carrie Gregory; Char Meng Chuor; Satharath Prom; Michele D. Spring; Chanthap Lon

doi:10.1128/AAC.02302-15

Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border

David L. Saunders^*, Suwanna Chaorattanakawee, Panita Gosi, Charlotte Lanteri, Sok Somethy, Worachet Kuntawunginn, Mali Ittiverakul, Soklyda Chann, Carrie Gregory, Char Meng Chuor, Satharath Prom, Michele D. Spring, Chanthap Lon

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Our recent report of dihydroartemisinin-piperaquine failure to treat Plasmodium falciparum infections in Cambodia adds new urgency to the search for alternative treatments. Despite dihydroartemisinin-piperaquine failure, and higher piperaquine 50% inhibitory concentrations (IC₅₀s) following reanalysis than those previously reported, P. falciparum remained sensitive to atovaquone (ATQ) in vitro. There were no point mutations in the P. falciparum cytochrome b ATQ resistance gene. Mefloquine, artemisinin, chloroquine, and quinine IC₅₀s remained comparable to those from other recent reports. Atovaquone-proguanil may be a useful stopgap but remains susceptible to developing resistance when used as blood-stage therapy.

Original language	English
Pages (from-to)	1896-1898
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	60
Issue number	3
DOIs	https://doi.org/10.1128/AAC.02302-15
State	Published - Mar 2016
Externally published	Yes

Access to Document

10.1128/AAC.02302-15

Cite this

Saunders, D. L., Chaorattanakawee, S., Gosi, P., Lanteri, C., Somethy, S., Kuntawunginn, W., Ittiverakul, M., Chann, S., Gregory, C., Chuor, C. M., Prom, S., Spring, M. D., & Lon, C. (2016). Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border. Antimicrobial Agents and Chemotherapy, 60(3), 1896-1898. https://doi.org/10.1128/AAC.02302-15

@article{247b04da97834e4f93c23f56aed3e494,

title = "Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border",

abstract = "Our recent report of dihydroartemisinin-piperaquine failure to treat Plasmodium falciparum infections in Cambodia adds new urgency to the search for alternative treatments. Despite dihydroartemisinin-piperaquine failure, and higher piperaquine 50% inhibitory concentrations (IC50s) following reanalysis than those previously reported, P. falciparum remained sensitive to atovaquone (ATQ) in vitro. There were no point mutations in the P. falciparum cytochrome b ATQ resistance gene. Mefloquine, artemisinin, chloroquine, and quinine IC50s remained comparable to those from other recent reports. Atovaquone-proguanil may be a useful stopgap but remains susceptible to developing resistance when used as blood-stage therapy.",

author = "Saunders, {David L.} and Suwanna Chaorattanakawee and Panita Gosi and Charlotte Lanteri and Sok Somethy and Worachet Kuntawunginn and Mali Ittiverakul and Soklyda Chann and Carrie Gregory and Chuor, {Char Meng} and Satharath Prom and Spring, {Michele D.} and Chanthap Lon",

year = "2016",

month = mar,

doi = "10.1128/AAC.02302-15",

language = "English",

volume = "60",

pages = "1896--1898",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology 1752 N St., NW, Washington, DC",

number = "3",

}

Saunders, DL, Chaorattanakawee, S, Gosi, P, Lanteri, C, Somethy, S, Kuntawunginn, W, Ittiverakul, M, Chann, S, Gregory, C, Chuor, CM, Prom, S, Spring, MD & Lon, C 2016, 'Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border', Antimicrobial Agents and Chemotherapy, vol. 60, no. 3, pp. 1896-1898. https://doi.org/10.1128/AAC.02302-15

TY - JOUR

T1 - Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border

AU - Saunders, David L.

AU - Chaorattanakawee, Suwanna

AU - Gosi, Panita

AU - Lanteri, Charlotte

AU - Somethy, Sok

AU - Kuntawunginn, Worachet

AU - Ittiverakul, Mali

AU - Chann, Soklyda

AU - Gregory, Carrie

AU - Chuor, Char Meng

AU - Prom, Satharath

AU - Spring, Michele D.

AU - Lon, Chanthap

PY - 2016/3

Y1 - 2016/3

N2 - Our recent report of dihydroartemisinin-piperaquine failure to treat Plasmodium falciparum infections in Cambodia adds new urgency to the search for alternative treatments. Despite dihydroartemisinin-piperaquine failure, and higher piperaquine 50% inhibitory concentrations (IC50s) following reanalysis than those previously reported, P. falciparum remained sensitive to atovaquone (ATQ) in vitro. There were no point mutations in the P. falciparum cytochrome b ATQ resistance gene. Mefloquine, artemisinin, chloroquine, and quinine IC50s remained comparable to those from other recent reports. Atovaquone-proguanil may be a useful stopgap but remains susceptible to developing resistance when used as blood-stage therapy.

AB - Our recent report of dihydroartemisinin-piperaquine failure to treat Plasmodium falciparum infections in Cambodia adds new urgency to the search for alternative treatments. Despite dihydroartemisinin-piperaquine failure, and higher piperaquine 50% inhibitory concentrations (IC50s) following reanalysis than those previously reported, P. falciparum remained sensitive to atovaquone (ATQ) in vitro. There were no point mutations in the P. falciparum cytochrome b ATQ resistance gene. Mefloquine, artemisinin, chloroquine, and quinine IC50s remained comparable to those from other recent reports. Atovaquone-proguanil may be a useful stopgap but remains susceptible to developing resistance when used as blood-stage therapy.

UR - http://www.scopus.com/inward/record.url?scp=84960332651&partnerID=8YFLogxK

U2 - 10.1128/AAC.02302-15

DO - 10.1128/AAC.02302-15

M3 - Article

C2 - 26711753

AN - SCOPUS:84960332651

SN - 0066-4804

VL - 60

SP - 1896

EP - 1898

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 3

ER -

Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border

Abstract

Access to Document

Fingerprint

Cite this